NDC 73309-029-01 - Dasatinib Monohydrate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 73309-029
- Requested NDC
- 73309-029-01
- Package NDCs from labels
- 73309-029-01
- Manufacturer
- BLUEBAY SHANDONG CO.,LTD
- Effective date
- 2021-12-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Dasatinib Monohydrate - BLUEBAY SHANDONG CO.,LTD | BLUEBAY SHANDONG CO.,LTD | 2021-12-10 | BULK INGREDIENT |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| DASATINIB | DASATINIB | Aurobindo Pharma Limited | 58ce42c6-10bd-4bb4-bf89-eae8ed82c339 | 2026-07-27 | Warnings, Adverse reactions | RBZ1571X5H |
| DASATINIB | DASATINIB | NorthStar RxLLC | f9b79d54-9bee-4c93-9c87-f3e65d91f146 | 2026-05-28 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | BluePoint Laboratories | 02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4 | 2026-03-05 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | Lupin Pharmaceuticals, Inc. | f60261dd-b8ea-4511-bed6-ad6d7f4dd828 | 2026-02-27 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | AvKARE | 43e078b9-4e0b-edeb-e063-6294a90a7586 | 2025-11-18 | Warnings, Adverse reactions | RBZ1571X5H |
| DASATINIB | DASATINIB | Alembic Pharmaceuticals Limited | 645fcf26-1b2f-40c5-881b-8effe02defbd | 2025-11-12 | Warnings, Adverse reactions | RBZ1571X5H |
| DASATINIB | DASATINIB | Alembic Pharmaceuticals Inc. | de3215a4-d098-4bc3-ad81-c7c9e3493872 | 2025-11-11 | Warnings, Adverse reactions | RBZ1571X5H |
| PHYRAGO | DASATINIB | Cycle Pharmaceuticals Ltd | 60976d1e-c415-417f-8168-4e07999a7281 | 2025-08-23 | Warnings, Adverse reactions | RBZ1571X5H |
| dasatinib | DASATINIB | Zydus Lifesciences Limited | 4eed6b7b-a09d-4d2e-a345-968dd68323bc | 2025-03-04 | RBZ1571X5H | |
| Dasatinib | DASATINIB | Dr.Reddys Laboratories Inc | eb5ddff2-6521-b461-43ac-80ff8660b20b | 2025-03-03 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | Biocon Pharma Inc. | 76e1833c-e105-5a3d-0f01-1330d8cc7ae1 | 2025-02-25 | Warnings, Adverse reactions | RBZ1571X5H |
| dasatinib | DASATINIB | Zydus Pharmaceuticals USA Inc. | 11703145-29ea-480a-9810-bc70663b783f | 2024-09-10 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | Apotex Corp. | 2ed87763-f018-abdb-c0ab-daa5e441b397 | 2024-09-04 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | Teva Pharmaceuticals, Inc. | 3000fd91-1b09-4d72-8522-1ca5e35ed956 | 2024-08-01 | Warnings, Adverse reactions | RBZ1571X5H |
| Dasatinib | DASATINIB | Prasco Laboratories | 1931e73f-918c-4d69-9543-de9643513d05 | 2024-07-09 | Warnings, Adverse reactions | RBZ1571X5H |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.